| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029743309 |
| P356 | DOI | 10.1186/1743-8462-4-8 |
| P932 | PMC publication ID | 1894804 |
| P698 | PubMed publication ID | 17543113 |
| P5875 | ResearchGate publication ID | 6293474 |
| P50 | author | Thomas Alured Faunce | Q3990567 |
| Joel Lexchin | Q88126817 | ||
| P2860 | cites work | Globalization and Health | Q24810318 |
| Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy | Q24812956 | ||
| Overview of the Hatch-Waxman Act and its impact on the drug development process. | Q34106723 | ||
| Torcetrapib and atorvastatin--should marketing drive the research agenda? | Q46562026 | ||
| The cost of privatization: extra payments to Medicare Advantage plans--updated and revised | Q79414520 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Canada | Q16 |
| Australia | Q408 | ||
| P304 | page(s) | 8 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Australia and New Zealand Health Policy | Q15753516 |
| P1476 | title | 'Linkage' pharmaceutical evergreening in Canada and Australia | |
| P478 | volume | 4 |
| Q57742556 | Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India |
| Q33939125 | CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs |
| Q33854927 | Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them? |
| Q96690175 | Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union |
| Q34483629 | Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants |
| Q57791553 | Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States |
| Q37030936 | Nanotechnology in global medicine and human biosecurity: private interests, policy dilemmas, and the calibration of public health law. |
| Q28486032 | Patents associated with high-cost drugs in Australia |
| Q51820456 | TRIPS-plus and access to medicines in China. |
| Q38674299 | The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries |
Search more.